Abbonarsi

Predictors of high cost after percutaneous coronary intervention: A review from Japanese multicenter registry overviewing the influence of procedural complications - 08/12/17

Doi : 10.1016/j.ahj.2017.08.008 
Taku Inohara, MD a, b, Yohei Numasawa, MD c, Takahiro Higashi, MD d, Ikuko Ueda, PhD a, Masahiro Suzuki, MD e, Kentaro Hayashida, MD a, Shinsuke Yuasa, MD a, Yuichiro Maekawa, MD a, Keiichi Fukuda, MD a, Shun Kohsaka, MD a,
a Department of Cardiology, Keio University School of Medicine, Tokyo, Japan 
b Duke Clinical Research Institute, Duke University Medical Center, Durham, NC 
c Department of Cardiology, Japanese Red Cross Ashikaga Hospital, Ashikaga, Japan 
d Division of Health Services Research, Center for Cancer Control and Information Services, National Cancer Center, Tokyo, Japan 
e Department of Cardiology, National Hospital Organization Saitama National Hospital, Saitama, Japan 

Reprint requests: Shun Kohsaka, MD, Department of Cardiology, Keio University School of Medicine, 35 Shinanomachi, Shinjuku-ku, Tokyo, Japan 160-8582.Department of CardiologyKeio University School of Medicine35 ShinanomachiShinjuku-kuTokyo160-8582Japan

Abstract

Background

Percutaneous coronary intervention (PCI) is widely used; however, factors of high-cost care after PCI have not been thoroughly investigated. We sought to evaluate the in-hospital costs related to PCI and identify predictors of high costs.

Methods

We extracted 2,354 consecutive PCI cases (1,243 acute cases, 52.8%) from 3 Japanese cardiovascular centers from 2011 to 2015. In-hospital complications were predefined under consensus definitions (eg, acute kidney injury [AKI]). We extracted the facility cost data for each patient's resource under the universal Japanese insurance system. We classified the patients into total cost quartiles and identified predictors for the highest quartile (“high-cost” group). In addition, incremental costs for procedure-related complications were calculated.

Results

During the study period, a total of 401 cases (17.0%) experienced procedure-related complications. The in-hospital acute and elective PCI costs per case were US $14,840 (interquartile range [IQR] 11,370-20,070) and US $11,030 (IQR 8929-14,670), respectively. After adjusting for baseline differences, any of the procedure-related complications remained an independent predictor of high costs (acute: odds ratio 1.66, 95% CIs 1.13-2.43; elective: odds ratio 3.73, 95% CIs 1.96-7.11). Notably, incremental costs were mainly attributed to AKI, which accounted for 37.5% of all incremental costs; it increased by US $9,840 for each AKI event, and the total cost increase reached US $2,588,035.

Conclusions

Procedure-related complications, particularly postprocedural AKI, were associated with higher costs in PCI. Further studies are required to evaluate prospectively whether the preventive strategy with a personalized risk stratification for AKI could save costs.

Il testo completo di questo articolo è disponibile in PDF.

Mappa


 Funding sources: The present study was funded by the Grants-in-Aid for Scientific Research from Japan Society for the Promotion of Science (grants 25460630 and 80571398) and Grant-in-Aid for Epidemiological Research Abroad from St Luke's International University.
 Conflict of interest: Dr Kohsaka received unrestricted research grant for the Department of Cardiology, Keio University School of Medicine, from Bayer Pharmaceutical Co, Ltd.
 Paul Hess, MD, MHS, served as guest editor for this article.


© 2017  Elsevier Inc. Tutti i diritti riservati.
Aggiungere alla mia biblioteca Togliere dalla mia biblioteca Stampare
Esportazione

    Citazioni Export

  • File

  • Contenuto

Vol 194

P. 61-72 - Dicembre 2017 Ritorno al numero
Articolo precedente Articolo precedente
  • Atrial fibrillation decision support tool: Population perspective
  • Mark H. Eckman, Alexandru Costea, Mehran Attari, Jitender Munjal, Ruth E. Wise, Carol Knochelmann, Matthew L. Flaherty, Pete Baker, Robert Ireton, Brett M. Harnett, Anthony C. Leonard, Dylan Steen, Adam Rose, John Kues
| Articolo seguente Articolo seguente
  • Outcomes in elderly and young patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention with bivalirudin versus heparin: Pooled analysis from the EUROMAX and HORIZONS-AMI trials
  • Khalid Qaderdan, Gerrit-Jan A. Vos, Thomas McAndrew, Philippe Gabriel Steg, Christian W. Hamm, Arnoud van‘t Hof, Roxana Mehran, Efthymios N. Deliargyris, Debra Bernstein, Gregg W. Stone, Jurriën M. ten Berg

Benvenuto su EM|consulte, il riferimento dei professionisti della salute.
L'accesso al testo integrale di questo articolo richiede un abbonamento.

Già abbonato a @@106933@@ rivista ?

Il mio account


Dichiarazione CNIL

EM-CONSULTE.COM è registrato presso la CNIL, dichiarazione n. 1286925.

Ai sensi della legge n. 78-17 del 6 gennaio 1978 sull'informatica, sui file e sulle libertà, Lei puo' esercitare i diritti di opposizione (art.26 della legge), di accesso (art.34 a 38 Legge), e di rettifica (art.36 della legge) per i dati che La riguardano. Lei puo' cosi chiedere che siano rettificati, compeltati, chiariti, aggiornati o cancellati i suoi dati personali inesati, incompleti, equivoci, obsoleti o la cui raccolta o di uso o di conservazione sono vietati.
Le informazioni relative ai visitatori del nostro sito, compresa la loro identità, sono confidenziali.
Il responsabile del sito si impegna sull'onore a rispettare le condizioni legali di confidenzialità applicabili in Francia e a non divulgare tali informazioni a terzi.


Tutto il contenuto di questo sito: Copyright © 2025 Elsevier, i suoi licenziatari e contributori. Tutti i diritti sono riservati. Inclusi diritti per estrazione di testo e di dati, addestramento dell’intelligenza artificiale, e tecnologie simili. Per tutto il contenuto ‘open access’ sono applicati i termini della licenza Creative Commons.